The prognosis for patients with advanced or metastatic NSCLC, either at initial diagnosis or recurrence, remains grim. The mainstay of standard of care has been chemotherapy with agents including platinum analogs, taxanes, vinca alkaloids, pemetrexed, vascular endothelial growth factor (VEGF) inhibitors. For patients with appropriate disease genotypes, first line therapy has also included, epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors.